Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD

PURPOSE: The efficacy and tolerability of GFF MDI (Bevespi Aerosphere(®)), a fixed-dose combination of glycopyrronium (GP)/formoterol fumarate dihydrate (FF) 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) delivered by metered dose inhaler (MDI) using innovative co-suspension...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Gary T, Rodriguez-Roisin, Roberto, Reisner, Colin, Maes, Andrea, Siddiqui, Shahid, Martin, Ubaldo J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868634/
https://www.ncbi.nlm.nih.gov/pubmed/29606861
http://dx.doi.org/10.2147/COPD.S154988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868634/
https://www.ncbi.nlm.nih.gov/pubmed/29606861
http://dx.doi.org/10.2147/COPD.S154988

Ejemplares similares